Reported about 5 hours ago
With the S&P 500's current high valuation and concerns about future performance, analysts suggest that Pfizer and AbbVie, both offering solid dividend yields, are positioned to outperform the index over the next ten years. Pfizer, with a 5.8% yield, is benefiting from new drug sales and acquisitions, while AbbVie, despite recent earnings declines due to patent losses, is seeing strong growth from new drugs like Skyrizi and Rinvoq.
Source: YAHOO